Healthcare & Life Sciences: Drug Pricing Digest — Number 62

CMS published two proposed mandatory CMMI models—Globe (Medicare Part B) and Guard (Medicare Part D)—that would impose MFN-based rebate calculations on relevant drugs, with comment periods ending Feb 23, 2026; Globe would run performance years Oct 1, 2026–Sep 30, 2031 and payments through Sep 30, 2033, while Guard would run Jan 1, 2027–Dec 31, 2033 with payments through Dec 31, 2035. Concurrently nine more manufacturers signed confidential pricing agreements with the administration (bringing the total to 14), IRA negotiation litigation persists, and a federal preliminary injunction (Dec 29, 2025) halted the planned Jan 1, 2026 340B rebate model—creating near-term regulatory uncertainty and potential downside pressure on pharmaceutical pricing, contracting, and reimbursement forecasts.

Analysis

Market structure: MFN-style Globe/Guard proposals and additional confidential manufacturer pacts compress pricing on Medicare Part B/D lines and favor payers and downstream aggregators (insurers, PBMs, specialty pharmacies). Direct losers are manufacturers with concentrated Medicare revenue (IV/infused biologics, oncology, high-price chronic therapies) where net selling price exposure could fall 10–30% on affected SKUs over 12–36 months; winners are UNH/CVS-sized insurers and low-cost biosimilar/generic suppliers that gain share. Cross-asset: expect 5–12% idiosyncratic downside stress in exposed pharma equities, modest (10–25bp) tightening in sovereign yields if federal deficit savings materialize, and widening credit spreads for small-cap biotech by 50–150bp.

Risk assessment: tail risks include a successful large-scale injunction (low prob but would spike volatility) or CMS finalizing broader-than-proposed rebates (high impact: incremental 15–25% revenue hits for top-exposed drugs). Immediate (days) risks = headline-driven volatility and intraday options reprices; short-term (weeks–months) = guidance cuts, downgrades and voluntary manufacturer deal disclosures; long-term (years) = structural lower price baselines altering R&D prioritization. Hidden dependencies: interaction with IRA rebates and confidential White House agreements can create double-rebate math and cliff revenue drops; litigation timelines (Feb 23 comment close, likely final rule Q2–Q3 2026) are key catalysts.

Trade implications: tactical longs: overweight large payers/retail PBMs (UNH, CVS) and select low-cost biosimilar manufacturers; shorts/hedges: large-cap pharma with >20% Medicare exposure (AMGN, ABBV, LLY) via small outright shorts or put purchases. Options: buy 3–6 month 10% OTM puts on AMGN/LLY sized to cover 0.5–1% portfolio risk; sell 3–6 month covered calls on insurer longs to harvest premium. Timing: scale into positions now (25–50% of target) and add/scrub at regulatory milestones—Feb 23, 2026 comment close and any court rulings.

Contrarian angles: consensus treats all pharma equally; it should not—companies with diversified commercial mixes, orphan drugs, or insulated hospital-administered high-need therapies may be minimally impacted and could be takeover targets. Historical parallels (post-ACA rebate changes) show 6–12 month overshoots then recovery; unintended consequences likely include accelerated M&A and vertical integration—favor acquirers with strong balance sheets (JNJ) and specialist funds buying distressed mid‑caps. If litigation weakens CMS reach, short gamma positions in insurers could reverse rapidly; therefore size protection conservatively.

Key Decisions for Investors

• Establish a 1.5% portfolio long in UnitedHealth (UNH) and a 1.0% long in CVS Health (CVS) now; target 8–15% upside over 6–12 months as payer margin capture accelerates, with a 8% stop-loss and sell-to-take-profit at +12–15%.
• Trim/hedge 25% of existing positions in Amgen (AMGN), AbbVie (ABBV), and Eli Lilly (LLY) immediately; if no exposure, initiate 0.5% short positions in AMGN and ABBV combined (0.25% each) to express concentrated-Medicare-risk, sizing to limit portfolio P&L draw to 2%.
• Buy 3–6 month 10% OTM puts on AMGN and LLY sized at 0.5% portfolio value each (cost-limited insurance) to protect against a 15–25% downside in exposed drugs; consider selling 3–6 month covered calls on UNH/CVS to fund part of the put premium.
• Allocate 1% to JNJ and 0.5–1% to select biosimilar manufacturers (e.g., small-cap targets or IBD/IBB exposure) on any post-final-rule selloff (>8% drawdown) or after the Feb 23, 2026 comment close if final rule narrows — these are tactical M&A/mean-reversion plays.